Advertisement: TTP
Advertisement: CJBS mid banner
Advertisement: Cambridge Network mid banner
St Johns Innovation Centre
Astrazeneca advertisement
Advertisement: PwC midbanner
Advertisement: Mills and Reeve mid banner
Advertisement: Barclays Corporate
27 November, 2017 - 12:57 By Tony Quested

F-star seeking fresh Awards glory

Business Weekly Awards F-Star

Not satisfied with winning the coveted Life Science Innovation Award in March, F-star Biotechnology is seeking a repeat success in this year’s competition.

The Cambridge business believes it has a new story to tell as it builds on a globally leading proposition.

For the uninitiated, F-star has become a leader in the development of bispecific antibodies, working in the fast-moving field of immuno-oncology. In June the company announced a collaboration with Merck for the development and commercialisation of five bispecific immuno-oncology antibodies, including F-star’s lead programme, in a deal that could reach €1 billion  in aggregate value. 

F-star has an innovative and flexible business model and this collaboration is held within the company’s fourth asset centric vehicle, F-star Delta. F-star has raised more than $200 million in non-dilutive cash and now employs nearly 90 people at its research facility on the Babraham Research Campus near Cambridge.

AstraZeneca and MedImmune sponsor the Life Science Innovation prize and judges were spoiled for choice for our March award.

AstraZeneca’s Shaun Grady said at the Awards dinner: “F–star is poised to dominate the bispecific antibody space in immuno-oncology through the application of highly efficient Modular Antibody Technology™ platform.

“This powerful platform enables the discovery of novel bispecific antibodies, which are selected for their potential to transform the treatment of cancer.”

The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including: AbbVie, Bristol-Myers Squibb, Merck KGaA and Denali Therapeutics.

F-star, led by CEO John Haurum, has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star’s management team has a well-established track record in building successful biotech companies and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors.

For more information about the Business Weekly Awards visit

• Pictured (left to right): Pierre Peotta (F-star), guest speaker Professor Steve Young and Shaun Grady (AstraZeneca) at the Business Weekly Awards in March.

For more information about the Business Weekly Awards visit

Newsletter Subscription

Stay informed of the latest news and features